MAFLD and NAFLD in the prediction of incident chronic kidney disease

被引:14
作者
Kwon, So Yoon [1 ]
Park, Jiyun [2 ]
Park, So Hee [1 ]
Lee, You-Bin [1 ]
Kim, Gyuri [1 ]
Hur, Kyu Yeon [1 ]
Koh, Janghyun [3 ]
Jee, Jae Hwan [3 ]
Kim, Jae Hyeon [1 ]
Kang, Mira [3 ,4 ]
Jin, Sang-Man [1 ]
机构
[1] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Endocrinol & Metab,Sch Med, 81 Irwon Ro, Seoul 06351, South Korea
[2] CHA Univ, CHA Bundang Med Ctr, Dept Internal Med, Div Endocrine & Metab,Sch Med, 59 Yatap Ro, Seongnam 14396, South Korea
[3] Sungkyunkwan Univ, Dept Hlth Promot Ctr, Ctr Hlth Promot, Samsung Med Ctr,Sch Med, 81 Irwon Ro, Seoul 06351, South Korea
[4] Sungkyunkwan Univ, Dept Digital Hlth, SAIHST, Seoul, South Korea
关键词
FATTY LIVER-DISEASE; METABOLIC SYNDROME; FIBROSIS; OBESITY;
D O I
10.1038/s41598-023-27762-6
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Whether metabolic dysfunction-associated fatty liver disease (MAFLD) can replace nonalcoholic fatty liver disease (NAFLD) is under debate. This study evaluated which definition better predicted incident chronic kidney disease (CKD). This was a 5.3-year (range, 2.8-8.3) retrospective cohort study of 21,713 adults who underwent at least two serial health examinations. Cox analyses were used to compare the risk of incident CKD among non-fatty liver disease (FLD) without metabolic dysregulation (MD; reference), non-FLD with MD, MAFLD-only, NAFLD-only, or both-FLD groups. Non-FLD with MD group (hazard ratio [HR] 1.23, 95% confidence interval [CI] 1.00-1.53), both-FLD group (HR 1.50, 95% CI 1.19-1.89), and MAFLD-only group (HR 1.97, 95% CI 1.49-2.60), but not NAFLD-only group (HR 1.06, 95% CI 0.63-1.79) demonstrated an increased risk of CKD. The increased risk of CKD was significant in MAFLD subgroups with overweight/obesity (HR 2.94, 95% CI 1.91-4.55), diabetes (HR 2.20, 95% CI 1.67-2.90), MD only (HR 1.50, 95% CI 1.19-1.89), excessive alcohol consumption (HR 2.71, 95% CI 2.11-3.47), and viral hepatitis (HR 2.38, 95% CI 1.48-3.84). The switch from NAFLD to MAFLD criteria may identify a greater number of individuals at CKD risk. The association was also significant in MAFLD patients with excessive alcohol consumption or viral hepatitis.
引用
收藏
页数:9
相关论文
共 50 条
[41]   MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study [J].
Han, Eugene ;
Chun, Ho Soo ;
Lee, Yong-ho ;
Lee, Jae Seung ;
Lee, Hye Won ;
Kim, Beom Kyung ;
Park, Jun Yong ;
Kim, Do Young ;
Lee, Byung-Wan ;
Kang, Eun Seok ;
Cha, Bong-Soo ;
Ahn, Sang Hoon ;
Kim, Seung Up .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 (09) :1598-1609
[42]   MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis [J].
Segura-Azuara, Nancy de los angeles ;
Varela-Chinchilla, Carlos Daniel ;
Trinidad-Calderon, Plinio A. .
FRONTIERS IN MEDICINE, 2022, 8
[43]   From NAFLD to MAFLD: Not just a change in the name [J].
Zeng, Jing ;
Fan, Jian-Gao .
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2022, 21 (06) :511-513
[44]   What's in a name? Renaming 'NAFLD' to 'MAFLD' [J].
Fouad, Yasser ;
Waked, Imam ;
Bollipo, Steven ;
Gomaa, Ahmed ;
Ajlouni, Yousef ;
Attia, Dina .
LIVER INTERNATIONAL, 2020, 40 (06) :1254-1261
[45]   From NAFLD to MAFLD: when pathophysiology succeeds [J].
Tilg, Herbert ;
Effenberger, Maria .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2020, 17 (07) :387-388
[46]   MAFLD: a multisystem disease [J].
Pipitone, Rosaria Maria ;
Ciccioli, Carlo ;
Infantino, Giuseppe ;
La Mantia, Claudia ;
Parisi, Stefanie ;
Tulone, Adele ;
Pennisi, Grazia ;
Grimaudo, Stefania ;
Petta, Salvatore .
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2023, 14
[47]   MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups [J].
Kim, Hyoeun ;
Lee, Chan Joo ;
Ahn, Sang Hoon ;
Lee, Kwan Sik ;
Lee, Byoung Kwon ;
Baik, Su Jung ;
Kim, Seung Up ;
Lee, Jung Il .
DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (10) :4919-4928
[48]   Comparison of NAFLD, MAFLD, and MASLD Prevalence and Clinical Characteristics in Asia Adults [J].
Huang, Xinjuan ;
Yu, Ruoling ;
Tan, Xinyun ;
Guo, Manjie ;
Xia, Yuanqin ;
Zou, Huihui ;
Liu, Xuelian ;
Qin, Chunxiang .
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2025, 15 (01)
[49]   From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights [J].
Gatzios, Alexandra ;
Rombaut, Matthias ;
Buyl, Karolien ;
De Kock, Joery ;
Rodrigues, Robim M. ;
Rogiers, Vera ;
Vanhaecke, Tamara ;
Boeckmans, Joost .
BIOMEDICINES, 2022, 10 (01)
[50]   What Is in a Name: from NAFLD to MAFLD and MASLD—Unraveling the Complexities and Implications [J].
Ramírez-Mejía M.M. ;
Méndez-Sánchez N. .
Current Hepatology Reports, 2023, 22 (4) :221-227